Recently, JCR announced collaboration agreements with Alexion and Angelini Pharma to develop new treatments using J-Brain Cargo technology for a neurodegenerative disease and epilepsy, respectively.

The first presentation will spotlight JR-479, an investigational BBB-penetrating β-Hexosaminidase A (rDNA origin) enzyme replacement therapy (ERT) that JCR is developing for the treatment of people ...